C. Geoffrey Davis
C. Geoffrey Davis, Ph.D joined the Company as a director in September 2007.
Currently, Dr. Davis is the CEO and Chairman of Angelica Therapeutics, Inc., a privately held biotechnology company.
In 1996, Dr. Davis founded Abgenix, Inc. in Fremont, California, where he served as the Chief
Scientific Officer and led the development of the XenoMouse® technology and was involved in the research and development of Vectibix®, a fully human monoclonal antibody approved for the treatment of colorectal cancer.
Dr. Davis also guided the discovery of 11 other antibodies
currently in clinical trials.
Abgenix was acquired by Amgen in early 2006.
Prior to founding Abgenix, Dr. Davis was a faculty member at UCSF, an investigator with the Howard Hughes Medical Institute, and Director of Immunology at both Repligen Corp. and Cell Genesys, Inc.
Dr. Davis
received his Ph.D. in immunology from the University of California, San Francisco and completed his postdoctoral work at Southwestern University.
He is the author of 37 publications and is an inventor on 11 issued patents.